Bintrafusp Alfa in High Mobility Group AT-Hook 2 (HMGA2) Expressing Triple Negative Breast Cancer
Condition: Triple Negative Breast Neoplasms
MeSH terms: Breast Neoplasms; Triple Negative Breast Neoplasms
Intervention: Bintrafusp alfa
Intervention description: Participants received an intravenous infusion of 1200 milligrams (mg) bintrafusp alfa once every 2 weeks until confirmed disease progression, unacceptable toxicity, study withdrawal or death.
Phase: Phase 2
Study type: Interventional
Primary purpose: Treatment
Intervention model: Single Group Assignment
Masking: None (Open Label)
Enrollment: 11.0
Sex: All
Minimum age: 18 Years
Healthy volunteers: No
Keywords: M7824; Bintrafusp alfa; Programmed death-ligand 1; Transforming growth factor-β (TGF-β); Breast Cancer; MS200647

Summary:

      The main purpose of this study was to evaluate bintrafusp alfa monotherapy in participants
      with triple negative breast cancer (TNBC) who express high levels of HMGA2 as determined by a
      centralized reverse transcriptase-polymerase chain reaction (RT-PCR) test.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Study participants have histologically or cytologically confirmed TNBC

          -  Absence of human epidermal growth factor receptor 2 (HER2), estrogen receptor, and
             progesterone receptor expression must be documented (criteria for defining TNBC are
             outlined in the protocol)

          -  Participants must have received at least one line of systemic therapy for metastatic
             disease and have progressed on the line of therapy immediately prior to study entry.
             There is no limit to the number of prior therapies

          -  Participants may prescreen for HMGA2 expression while on preceding treatment, however
             screening should only occur if in the opinion of the Investigator, the participant
             would likely be eligible for study within 6 months

          -  Participants must have measurable disease

          -  Availability of either archival tumor tissue or fresh core or excisional biopsy of a
             tumor lesion (primary or metastatic, excluding bone biopsies) is mandatory to
             determine HMGA2 expression level prior to enrollment

          -  HMGA2 high tumor expression is required and will be determined by a central lab

          -  Participants who have Eastern Cooperative Oncology Group (ECOG) PS of 0 to 1

          -  Participants have a life expectancy greater than or equal to (>=) 12 weeks as judged
             by the Investigator at study start

          -  Participants have adequate hematological, hepatic and renal and coagulation function
             as defined in the protocol

          -  Participants with known Human Immunodeficiency Virus (HIV) infections are in general
             eligible if the criteria as defined in the protocol are met (Food and Drug
             Administration [FDA] Guidance on Cancer Clinical Trial Eligibility, March 2019)

          -  Participants with hepatitis B virus (HBV) and/or hepatitis C virus (HCV) infections
             are in general eligible if the criteria as defined in the protocol are met (FDA
             Guidance on Cancer Clinical Trial Eligibility, March 2019)

          -  Other protocol defined inclusion criteria could apply

        Exclusion Criteria:

          -  Participants with active central nervous system (CNS) metastases causing clinical
             symptoms or metastases that require therapeutic intervention are excluded.
             Participants with a history of treated CNS metastases (by surgery or radiation
             therapy) are not eligible unless they have fully recovered from treatment,
             demonstrated no progression for at least 4 weeks, and are not using steroids for at
             least 7 days prior to the start of study intervention

          -  Participants must not have received prior cancer treatment with any other
             immunotherapy or checkpoint inhibitors, or any other immune-modulating monoclonal
             antibody

          -  Participants that received any organ transplantation, including stem-cell
             transplantation, but with the exception of transplants that do not require
             immunosuppression

          -  Participants with significant acute or chronic infections

          -  Participants with active autoimmune disease that might deteriorate when receiving an
             immunostimulatory agent

          -  Participants with clinically significant cardiovascular/cerebrovascular disease
             including: cerebral vascular accident/stroke, myocardial infarction, unstable angina,
             congestive heart failure, or serious cardiac arrhythmia

          -  Other protocol defined exclusion criteria could apply